NBP
NovaBridge Biosciences NASDAQ Listed Jan 17, 2020$1.50
-4.46%
vs $1.57
Mkt Cap $172.9M
52w Low $1.46
0.8% of range
52w High $6.79
50d MA $2.05
200d MA $3.40
P/E (TTM)
-3.1x
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.0x
ROE
-20.0%
P/FCF
-7.0x
RSI (14)
29.30
ATR (14)
$0.13
Beta
1.74
50d MA
$2.05
200d MA
$3.40
Avg Volume
679.2K
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
2440 Research Boulevard · Rockville, MD 20850 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7, 2026 | AMC | -0.04 | -0.22 | -528.6% | 2.48 | +5.6% | -1.2% | -0.8% | -2.9% | +1.7% | +5.8% | — |
| Dec 18, 2025 | AMC | -0.01 | -0.25 | -1801.5% | 3.96 | +0.5% | +5.8% | +4.8% | +2.5% | +2.9% | -6.3% | — |
| Nov 12, 2025 | AMC | -0.04 | -0.01 | +76.5% | 4.22 | -0.9% | -1.2% | -0.5% | +5.3% | +3.9% | -0.2% | — |
| May 15, 2025 | AMC | -0.06 | -0.04 | +33.3% | 0.89 | -3.1% | +1.7% | +1.2% | +0.3% | +3.2% | +11.3% | — |
| Apr 4, 2025 | AMC | -0.06 | -0.11 | -83.3% | 0.68 | +13.2% | -8.8% | +10.6% | +0.4% | -2.1% | -0.7% | — |
| Nov 14, 2024 | AMC | -0.16 | -0.25 | -56.2% | 1.07 | +1.9% | -2.8% | -2.9% | -5.6% | +2.8% | -2.1% | — |
| Aug 28, 2024 | AMC | -0.51 | -0.07 | +86.3% | 1.17 | +0.9% | -4.3% | +0.9% | -7.1% | +0.0% | +0.0% | — |
| Jun 5, 2024 | AMC | — | 0.04 | — | 1.90 | +0.5% | -1.6% | +0.5% | -1.1% | +0.0% | -0.5% | — |
| Mar 29, 2024 | AMC | -0.10 | -0.59 | -513.0% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.57 | — | — | — | — | — | — | — | — | — |
| Aug 17, 2023 | AMC | -0.26 | -0.64 | -146.7% | 2.30 | -0.4% | -8.7% | -9.3% | +3.7% | -0.8% | -3.6% | — |
| Mar 31, 2023 | AMC | -0.49 | -0.68 | -37.9% | 3.46 | +1.7% | +6.4% | -1.4% | -2.5% | +8.8% | -7.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.48 | $2.62 | +5.6% | -1.2% | -0.8% | -2.9% | +1.7% | +5.8% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.83 | $3.10 | +9.5% | +2.5% | -0.7% | -2.1% | -4.6% | -4.8% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.33 | $3.47 | +4.2% | +11.1% | -6.2% | -1.4% | -0.9% | -4.4% |
| Oct 24 | BTIG | Maintains | Buy → Buy | — | $4.39 | $4.40 | +0.2% | -3.9% | +11.4% | -1.3% | -0.2% | -1.7% |
| Oct 17 | BTIG | Maintains | Buy → Buy | — | $6.56 | $6.30 | -4.0% | -12.0% | -9.5% | -1.7% | -6.0% | -8.9% |
| Sep 10 | BTIG | Maintains | Buy → Buy | — | $4.60 | $4.25 | -7.6% | -9.1% | -6.7% | +4.9% | -11.5% | +2.8% |
| Sep 8 | Needham | Maintains | Buy → Buy | — | $4.38 | $4.43 | +1.1% | -2.5% | +7.7% | -9.1% | -6.7% | +4.9% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.52 | $4.38 | -3.1% | +4.2% | +8.1% | -5.3% | +7.5% | -13.1% |
| Aug 20 | Needham | Maintains | Buy → Buy | — | $4.21 | $4.15 | -1.4% | +7.4% | +4.2% | +8.1% | -5.3% | +7.5% |
| Jul 9 | Needham | Maintains | Buy → Buy | — | $2.20 | $2.22 | +0.9% | +5.0% | -11.3% | +3.9% | +0.5% | -1.9% |
| Jul 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.20 | $2.22 | +0.9% | +5.0% | -11.3% | +3.9% | +0.5% | -1.9% |
| Jun 27 | Needham | Maintains | Buy → Buy | — | $2.02 | $2.12 | +5.0% | +27.2% | -5.8% | -3.3% | -2.1% | -6.1% |
| Sep 24 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 4 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Aug 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.37 | $2.51 | +5.9% | -3.0% | -8.7% | -9.3% | +3.7% | -0.8% |
| Aug 17 | Needham | Maintains | Buy → Buy | — | $2.37 | $2.51 | +5.9% | -3.0% | -8.7% | -9.3% | +3.7% | -0.8% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.37 | $2.51 | +5.9% | -3.0% | -8.7% | -9.3% | +3.7% | -0.8% |
| Jun 4 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 19 | Needham | Maintains | Buy → Buy | — | $3.42 | $3.30 | -3.5% | -0.6% | -5.6% | +4.4% | -5.1% | -1.3% |
| Apr 2 | Piper Sandler | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 2 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.83 | $6.02 | +3.3% | +2.6% | +2.5% | +2.6% | -6.0% | -5.4% |
| Aug 30 | Needham | Maintains | Buy → Buy | — | $5.83 | $6.02 | +3.3% | +2.6% | +2.5% | +2.6% | -6.0% | -5.4% |
| Aug 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.00 | $5.80 | -3.3% | -2.8% | +2.6% | +2.5% | +2.6% | -6.0% |
| Aug 16 | Needham | Maintains | Buy → Buy | — | $7.97 | $7.90 | -0.9% | +0.0% | -14.3% | -9.4% | -2.9% | -4.3% |
| May 30 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.85 | $17.04 | +1.1% | +15.1% | -2.3% | -14.3% | +7.8% | +5.3% |
| Oct 31 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.18 | $62.84 | -2.1% | +10.5% | +1.3% | -1.0% | +0.8% | +4.0% |
| Jun 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $74.11 | $73.97 | -0.2% | +2.6% | -3.6% | -2.1% | +0.9% | -3.0% |
| Jun 2 | Daiwa Capital | Maintains | Buy → Buy | — | $80.00 | $81.40 | +1.8% | -4.8% | -0.1% | +2.5% | -4.5% | -0.6% |
| Mar 15 | Needham | Maintains | Buy → Buy | — | $55.01 | $56.80 | +3.3% | -4.3% | +3.9% | +3.7% | -6.1% | -0.5% |
| Mar 3 | H.C. Wainwright | Maintains | Buy → Buy | — | $58.90 | $59.67 | +1.3% | +4.0% | -9.3% | -11.3% | +1.5% | +2.5% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.97 | $63.55 | -0.7% | -7.9% | +4.0% | -9.3% | -11.3% | +1.5% |
| Mar 2 | H.C. Wainwright | Maintains | Buy → Buy | — | $63.97 | $63.55 | -0.7% | -7.9% | +4.0% | -9.3% | -11.3% | +1.5% |
| Feb 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $57.99 | $59.59 | +2.8% | +0.8% | +1.2% | +8.1% | -7.9% | +4.0% |
| Dec 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.99 | $39.27 | +3.4% | +7.2% | -5.5% | -1.4% | -2.4% | +0.2% |
| Aug 26 | CMB International | Maintains | Buy → Buy | — | $30.28 | $31.09 | +2.7% | -0.3% | +3.5% | -0.8% | +27.2% | -11.3% |
| Jul 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.24 | $29.65 | +5.0% | +5.5% | +2.4% | -1.0% | -2.7% | +8.7% |
| Feb 14 | CICC | Maintains | Outperform → Outperform | — | $11.08 | $11.15 | +0.6% | -2.4% | -1.7% | +0.1% | +14.1% | -1.2% |
| Feb 12 | China Renaissance | Maintains | Buy → Buy | — | $11.18 | $11.20 | +0.2% | -1.6% | +0.7% | -2.4% | -1.7% | +0.1% |
| Feb 11 | Jefferies | Maintains | Buy → Buy | — | $11.00 | $11.26 | +2.4% | +1.6% | -1.6% | +0.7% | -2.4% | -1.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Xu Cong Claire | SVP, Clinical Development | Sell | 3,494 | $3.94 | $14K | 290,154 | +2.34% | +1.92% |
| May 14, 2026 | Cao Sean Wuxiong | See Remarks | Sell | 21,399 | $1.99 | $43K | 35,073 | -1.75% | +5.08% |
| Apr 24, 2026 | Hagler Mark Arnold | See Remarks | Buy | 230,000 | $2.51 | $577K | 230,000 | -1.67% | +1.46% |
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 7,571,004 | $30M | Added | Dec 2025 |
| 2 | Janus Henderson Group Plc | 6,032,650 | $15M | New | Mar 2026 |
| 3 | Candriam S.c.a. | 1,132,563 | $5M | — | Dec 2025 |
| 4 | Point72 Asset Management | 1,389,403 | $3M | Reduced | Mar 2026 |
| 5 | Woodline Partners Lp | 700,000 | $2M | Reduced | Mar 2026 |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 191,714 | $763K | Added | Dec 2025 |
| 7 | Barclays Plc | 299,299 | $736K | Reduced | Mar 2026 |
| 8 | Renaissance Technologies Llc | 272,412 | $670K | New | Mar 2026 |
| 9 | Taikang Asset Management (Hong Kong) Co Ltd | 170,931 | $420K | Added | Mar 2026 |
| 10 | Citadel Advisors Llc | 166,616 | $410K | New | Mar 2026 |
| 11 | Hrt Financial Lp | 107,524 | $264K | New | Mar 2026 |
| 12 | Axq Capital, Lp | 83,330 | $205K | New | Mar 2026 |
| 13 | Dymon Asia Capital (Singapore) Pte. Ltd. | 80,400 | $198K | — | Mar 2026 |
| 14 | Leonteq Securities Ag | 80,000 | $197K | Added | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 73,102 | $180K | Reduced | Mar 2026 |
| 16 | Ubs Group Ag | 63,541 | $156K | Reduced | Mar 2026 |
| 17 | Jane Street Group, Llc | 32,581 | $130K | Added | Dec 2025 |
| 18 | Jpmorgan Chase & Co | 57,489 | $129K | Reduced | Mar 2026 |
| 19 | Invesco Ltd. | 28,161 | $69K | Added | Mar 2026 |
| 20 | China Universal Asset Management Co., Ltd. | 16,940 | $67K | New | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 13
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Biotechnology ETF | 539,518 | $1M | Mar 2026 |
| 2 | Barrons 400 ETF | 119,062 | $391K | Feb 2026 |
| 3 | Fidelity Nasdaq Composite Index Fund | 56,753 | $186K | Feb 2026 |
| 4 | THE EMERGING MARKETS SMALL CAP SERIES | 48,055 | $159K | Jan 2026 |
| 5 | Emerging Markets Social Core Equity Portfolio | 23,312 | $77K | Jan 2026 |
| 6 | EMERGING MARKETS CORE EQUITY 2 PORTFOLIO | 20,035 | $66K | Jan 2026 |
| 7 | Invesco NASDAQ Future Gen 200 ETF | 17,187 | $56K | Feb 2026 |
| 8 | World ex U.S. Core Equity Portfolio | 14,442 | $48K | Jan 2026 |
| 9 | Emerging Markets Sustainability Core 1 Portfolio | 9,306 | $31K | Jan 2026 |
| 10 | ActivePassive International Equity ETF | 8,319 | $27K | Feb 2026 |
| 11 | Invesco Nasdaq Biotechnology ETF | 5,799 | $19K | Feb 2026 |
| 12 | ProShares Ultra Nasdaq Biotechnology | 4,801 | $16K | Feb 2026 |
| 13 | ULTRACHINA PROFUND | 3,935 | $13K | Jan 2026 |
Valuation
Market Cap
$172.9M
Enterprise Value
-$67.2M
P/E (TTM)
-3.13x
Forward P/E
—
PEG Ratio
0.65x
P/B
0.08x
P/S
—
P/FCF
-6.97x
EV/EBITDA
—
Shares Out
95.8M
Financials (TTM)
Revenue
$0
Net Income
-$46.3M
EBITDA
-$93.4M
Free Cash Flow
-$20.6M
Op Cash Flow
-$20.6M
EPS Basic
$-0.48
EPS Diluted
$-0.48
EPS Forward
$-3.34
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$260.5M
Total Liab.
$29.6M
Total Equity
$230.9M
Cash
$210.8M
LT Debt
$0
Book Value/Sh
$18.71
Debt/Equity
0.01x
Current Ratio
8.09
Quick Ratio
8.09
Returns & Growth
ROE
-20.0%
ROA
-17.8%
ROIC
-274.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+89.2%
Price Returns
2W
-4.2%
1M
-25.5%
3M
-43.9%
6M
-52.1%
12M
+40.5%
Technicals
52W High
$6.79
52W Low
$1.46
50d MA
$2.05
200d MA
$3.40
RSI (14)
29.30
ATR (14)
$0.13
Beta
1.74
Avg Volume
679K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$9.00
High
$9.00
Low
$9.00
Median
$9.00
Data updated apr 26, 2026 2:21pm
· Source: financialmodelingprep.com